SI
Request removal
SemaThera Inc
SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
URLs
- website: http://www.semathera.com
- twitter: https://twitter.com/Sema_Thera
- linkedin: http://www.linkedin.com/company/semathera-inc
Get valid emails for people working at SemaThera Inc and 200M other companies
20 free emails each month. No credit card required.
500M
Business Profiles
20M
Company Profiles
200M
Email addresses
98%+
Email Delivery
SemaThera Inc's headquarter address
SemaThera Inc's industries
research
SemaThera Inc's technology
Google Cloud Hosting
Google Font API
Mobile Friendly
Nginx
Outlook
WP Engine
WordPress.org
People working at SemaThera Inc
VB
Véronique Bougie
Chief Operating Officer
Westmount, Quebec, Canada
GC
Garth Cumberlidge
President, Director & Chief Executive Officer
Westmount, Quebec, Canada
MS
Mike (Przemyslaw) Sapieha
Founder & Chief Scientific Officer
Westmount, Quebec, Canada
MR
Maxime Ranger
Advisor to CEO
Westmount, Quebec, Canada
FB
François Binet
Team Project Leader
Westmount, Quebec, Canada
ED
Elizabeth Douville
Board Member
Westmount, Quebec, Canada
MB
Michelle Barbagallo
Scientist
Westmount, Quebec, Canada
You can find 7 people working at SemaThera Inc on FinalScout. Create a free account to view details including email addresses.
Find emails from LinkedIn for free
20 free emails each month. No credit card required.
Regular search results
Search for leads on linkedin.com and scrape the search results
Sales Navigator search results
Search for leads in LinkedIn sales navigator and scrape the search results
Group members
Scrape members from any LinkedIn group without joining it
Event attendees
Scrape event attendees from any LinkedIn event